Instagram Outage Disrupts Thousands of U.S. Users 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026 
Samsung Bioepis Co. Ltd.'s commercial partner Organon will supply its Hadlima autoimmune disease treatment to the United States after winning an order from the U.S. Department of Veterans Affairs. It was agreed that U.S.-based Organon would deliver the biosimilar Hadlima drugs for five years.
Organon will now deliver Hadlima biosimilar treatment to the Department of Veterans Affairs (V.A.). This well-known drug is mainly used for medicating rheumatoid arthritis, spondyloarthritis, and psoriasis. According to The Korea Economic Daily, AbbVie Inc., a pharmaceutical company headquartered in North Chicago, Illinois, developed the original drug.
Orders from the U.S.
The latest order was revealed by Organon, the partner company of Samsung Bioepis based in the U.S. On Wednesday, Feb. 21, the firm said that Organon won a bidding contract to supply Hadlima to the American government agency. Consequently, Organon will supply Hadlima to hospitals under the Ministry of Veterans Affairs for the next five years.
The Veterans Affairs
The VA is a government agency for veterans in the United States. It provides benefits in various fields, such as medical care and finance, and is building a general hospital-level hospital network and medical infrastructure throughout the United States.
"America's veterans deserve access to quality medicines at a lower cost. We are proud to support the more than nine million people enrolled in the VA healthcare system through this collaboration, which is a great example of industry and public sector working together," Kevin Ali, Organon CEO, said in a press release. "We applaud the VA for its leadership in championing biosimilars and including all three of Organon's biosimilars available in the US on its formulary."
Photo by: Organon Media
